AbCellera Biologics (ABCL) has become a focus after reporting quarterly results that exceeded earnings and revenue estimates, along with encouraging Phase 2 and Phase 1 data for key antibody programs ...
Source LinkAbCellera Biologics (ABCL) has become a focus after reporting quarterly results that exceeded earnings and revenue estimates, along with encouraging Phase 2 and Phase 1 data for key antibody programs ...
Source Link
Comments